Suppr超能文献

用于体外同时研究消化和吸收的脂肪分解渗透装置。

Lipolysis-Permeation Setup for Simultaneous Study of Digestion and Absorption in Vitro.

机构信息

Department of Pharmacy , Uppsala University , Uppsala Biomedical Center , P.O. Box 580, SE-751 23 Uppsala , Sweden.

出版信息

Mol Pharm. 2019 Mar 4;16(3):921-930. doi: 10.1021/acs.molpharmaceut.8b00811. Epub 2019 Jan 29.

Abstract

Lipid-based formulations (LBFs) are a delivery strategy to enhance intestinal absorption of poorly water-soluble drugs. LBF performance is typically evaluated by in vitro lipolysis studies, but these do not accurately predict the in vivo performance. One possible reason is the absence of an absorptive membrane driving sink conditions in the serosal compartment. To explore the impact of absorption under sink conditions on the performance evaluation, we developed a lipolysis-permeation setup that allows simultaneous investigation of intestinal digestion of an LBF and drug absorption. The setup consists of two chambers, an upper one for digestion (luminal), and a lower, receiving one (serosal), separated by a Caco-2 monolayer. Digestions were performed with immobilized lipase, instead of the pancreatic extract typically used during lipolysis, since the latter has proven incompatible with Caco-2 cells. Danazol-loaded LBFs were used to develop the setup, and fenofibrate-loaded LBFs were used to establish an in vitro in vivo correlation. As in regular lipolysis studies, our setup allows for the evaluation of (i) the extent of digestion and (ii) drug distribution in different phases present during lipolysis of drug-loaded LBFs (i.e., oil, aqueous, and solid phase). In addition, our setup can determine drug permeation across Caco-2 monolayers and hence, the absorptive flux of the compound. The presence of the absorptive monolayer and sink conditions tended to reduce aqueous drug concentrations and supersaturation in the digestion chamber. The drug transfer across the Caco-2 membrane accurately reflected in vivo drug exposure upon administration of three different LBFs loaded with fenofibrate, where the traditional lipolysis setup failed to predict in vivo performance. As the new setup reflects the dynamic processes occurring in the gastrointestinal tract, it is a valuable tool that can be used in the development of LBFs prior to in vivo studies.

摘要

基于脂质的制剂(LBF)是一种增强亲脂性差的药物肠道吸收的递药策略。LBF 的性能通常通过体外脂肪分解研究来评估,但这些研究并不能准确预测体内性能。一个可能的原因是缺乏吸收膜,无法在浆膜腔中形成吸收的吸收相。为了探索在吸收相下吸收对性能评估的影响,我们开发了一种脂肪分解-渗透装置,允许同时研究 LBF 的肠道消化和药物吸收。该装置由两个腔室组成,上腔室用于消化(腔室),下腔室用于接收(浆膜),由 Caco-2 单层隔开。消化是用固定化脂肪酶进行的,而不是通常在脂肪分解中使用的胰腺提取物,因为后者已被证明与 Caco-2 细胞不兼容。我们使用载有达那唑的 LBF 来开发该装置,并使用载有非诺贝特的 LBF 来建立体外-体内相关性。与常规脂肪分解研究一样,我们的装置允许评估(i)消化程度和(ii)载药 LBF 脂肪分解过程中存在的不同相(即油相、水相和固相等)中药物的分布。此外,我们的装置可以确定药物穿过 Caco-2 单层的渗透情况,从而确定化合物的吸收通量。吸收膜的存在和吸收相条件往往会降低消化腔中的水相药物浓度和过饱和度。当用三种不同的载有非诺贝特的 LBF 进行给药时,药物穿过 Caco-2 膜的转移准确反映了体内暴露情况,而传统的脂肪分解装置未能预测体内性能。由于新装置反映了胃肠道中发生的动态过程,因此它是一种在体内研究之前可用于 LBF 开发的有价值的工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70c4/6437649/11d3220238bc/mp-2018-00811c_0001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验